|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11147817||SHILPA||Pharmaceutical composition of pemetrexed|| |
(11 years from now)
Pemetrexed is owned by Shilpa.
Pemetrexed contains Pemetrexed Disodium.
Pemetrexed has a total of 1 drug patent out of which 0 drug patents have expired.
Pemetrexed was authorised for market use on 22 May, 2023.
Pemetrexed is available in solution;intravenous dosage forms.
The generics of Pemetrexed are possible to be released after 26 March, 2035.
Market Authorisation Date: 22 May, 2023
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic